ProShare Advisors
ALXO icon

ProShare Advisors’s ALX Oncology ALXO Stock Holding History

ProShare Advisors’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-9,579
Closed -$205K – 2202
2021
Q4 		$205K Sell
9,579
-1,315
-12% -$56.7K ﹤0.01% 2018
2021
Q3 		$805K Sell
10,894
-934
-8% -$62.3K ﹤0.01% 984
2021
Q2 		$647K Buy
11,828
+1,665
+16% +$99.6K ﹤0.01% 1343
2021
Q1 		$749K Buy
10,163
+2,278
+29% +$179K ﹤0.01% 1167
2020
Q4 		$680K Buy
+7,885
New +$474K ﹤0.01% 1079

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

ProShare Advisors's ALXO Position: Q1 2022 in Review

ProShare Advisors sold out of ALX Oncology (ALXO) in Q1 2022, closing a stake of 9,579 shares — an estimated $205K sold.

ProShare Advisors first reported a position in ALXO in Q4 2020 and held it in 5 quarters. The position peaked at $805K in Q3 2021. 96 funds tracked by Wall St. Rank hold ALXO as of Q1 2022.

  • ProShare Advisors reported no remaining ALX Oncology position as of Q1 2022 after selling out during the quarter.
  • ProShare Advisors sold 9,579 ALX Oncology shares in Q1 2022, an estimated $205K.
  • ProShare Advisors first reported a position in ALX Oncology in Q4 2020 and held it in 5 quarters.
  • ProShare Advisors's ALX Oncology position peaked at $805K in Q3 2021.
  • 96 funds tracked by Wall St. Rank held ALX Oncology as of Q1 2022.

Based on ProShare Advisors's 13F filing for Q1 2022, filed 10 May 2022.